{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Albumin: low"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Albumin: high"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Calcium: low"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Calcium: high"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Glucose: low"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Glucose: high"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Potassium: low"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Potassium: high"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Sodium: low"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Sodium: high"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"PCI ranges for the clinical chemistry parameters were as follows: albumin (low: \\<0.86 g/L), calcium (low: \\<0.91 mmol/L and high: \\>1.06 mmol/L), glucose (low: \\<0.71 mmol/L and high: \\>1.41 mmol/L), magnesium (low: \\<0.63 mmol/L and high: \\>1.03 mmol/L), phosphorous (low: \\<0.80 mmol/L and high: \\>1.14 mmol/L), potassium (low: \\<0.86 mmol/L and high: \\>1.10 mmol/L), sodium (low: \\<0.96 mmol/L and high: \\>1.03 mmol/L), and total CO2 (low: \\<0.86 mmol/L and high: \\>1.14 mmol/L).","groups":[{"description":"Participants received GSK3039294 600 mg, capsules, orally, under fed condition, QD for 7 days in cohort 3.","id":"OG000","title":"Part B: Cohort 3- GSK3039294 600 mg QD"},{"description":"Participants were planned to receive repeat dose of GSK3039294 for 21 days in cohort 4a. The dose level was to be adjusted once during the 21 days. Cohort 4a was not initiated due to safety reasons during conduct of Part B (Cohort 3).","id":"OG001","title":"Part B: Cohort 4a- GSK3039294"},{"description":"Participants were planned to receive repeat dose of GSK3039294 for 21 days in cohort 4b. The dose level was to be adjusted once during the 21 days. Cohort 4b was not initiated due to safety reasons during conduct of Part B (Cohort 3).","id":"OG002","title":"Part B: Cohort 4b- GSK3039294"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety population. Data was not collected as study was terminated, due to safety reasons during conduct of Part B (end of Cohort 3) whereas Cohort 4a and 4b were not recruited in Part B.","reportingStatus":"POSTED","timeFrame":"Cohort 3 and 4: Up to Day 3","title":"Part B: Number of Participants With Emergent Clinical Chemistry by PCI Criteria","type":"PRIMARY","unitOfMeasure":"Participants"}